Ex-GSK CEO An­drew Wit­ty goes biotech, tak­ing a board seat at G1

An­drew Wit­ty and G1 CEO Mark Vel­le­ca File Pho­to

An­drew Wit­ty may have just stepped out of the top job at the multi­na­tion­al phar­ma gi­ant Glax­o­SmithK­line, but he isn’t leav­ing bio­phar­ma.

G1 Ther­a­peu­tics $GTHX tells me that Sir An­drew is join­ing the board of di­rec­tors at the Re­search Tri­an­gle Park, NC-based biotech, in a clear coup for the new­ly pub­lic com­pa­ny.

“I had met him a cou­ple of times,” says CEO Mark Vel­le­ca. “Glax­o­SmithK­line has a pres­ence in North Car­oli­na. I was im­pressed by his re­marks on where the in­dus­try is head­ing, is­sues of ac­cess,” mar­ket­ing and more. “The fact that he has led the de­vel­op­ment of mul­ti­ple prod­ucts that have been sold glob­al­ly, ben­e­fit­ing pa­tients from all dif­fer­ent ther­a­peu­tic ar­eas was an ex­pe­ri­ence base we didn’t have on the board.”

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN